Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated
- 1 October 2008
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 118 (10), 3291-3300
- https://doi.org/10.1172/jci35876
Abstract
Hutchinson-Gilford progeria syndrome (HGPS), a rare disease that results in what appears to be premature aging, is caused by the production of a mutant form of prelamin A known as progerin. Progerin retains a farnesyl lipid anchor at its carboxyl terminus, a modification that is thought to be important in disease pathogenesis. Inhibition of protein farnesylation improves the hallmark nuclear shape abnormalities in HGPS cells and ameliorates disease phenotypes in mice harboring a knockin HGPS mutation (LmnaHG/+). The amelioration of disease, however, is incomplete, leading us to hypothesize that nonfarnesylated progerin also might be capable of eliciting disease. To test this hypothesis, we created knockin mice expressing nonfarnesylated progerin (LmnanHG/+). LmnanHG/+ mice developed the same disease phenotypes observed in LmnaHG/+ mice, although the phenotypes were milder, and mouse embryonic fibroblasts (MEFs) derived from these mice contained fewer misshapen nuclei. The steady-state levels of progerin in LmnanHG/+ MEFs and tissues were lower, suggesting a possible explanation for the milder phenotypes. These data support the concept that inhibition of protein farnesylation in progeria could be therapeutically useful but also suggest that this approach may be limited, as progerin elicits disease phenotypes whether or not it is farnesylated.Keywords
This publication has 45 references indexed in Scilit:
- A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in CellsPublished by Elsevier BV ,2008
- Eliminating the Synthesis of Mature Lamin A Reduces Disease Phenotypes in Mice Carrying a Hutchinson-Gilford Progeria Syndrome AllelePublished by Elsevier BV ,2008
- Phenotype and Course of Hutchinson–Gilford Progeria SyndromeNew England Journal of Medicine, 2008
- Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson–Gilford progeria syndrome mutationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- “Laminopathies”: A wide spectrum of human diseasesExperimental Cell Research, 2007
- Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human agingProceedings of the National Academy of Sciences of the United States of America, 2007
- A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutationJCI Insight, 2006
- A progeroid syndrome in mice is caused by defects in A-type laminsNature, 2003
- Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System DiseaseNew England Journal of Medicine, 1999
- The Hutchinson-Gilford progeria syndromeThe Journal of Pediatrics, 1972